Literature DB >> 6327520

Central and peripheral indices of sympathetic activity after blood pressure lowering with enalapril (MK-421) or hydralazine in normotensive rats.

O Kohlmann, M Bresnahan, H Gavras.   

Abstract

Various antihypertensive drugs have different effects on vasoactive mechanisms. In normotensive Wistar rats, we investigated the effects on plasma and tissue catecholamines of chronic treatment with two agents: MK-421, an angiotensin converting-enzyme inhibitor (CEI), and hydralazine, a vascular smooth muscle relaxant. Both agents lowered blood pressure via arteriolar dilation, to the same final level. However, hydralazine stimulated the renin-angiotensin system and elevated the plasma norepinephrine (NE) and epinephrine (E) levels, whereas MK-421 did not. In MK-421-treated animals, NE, E, and the ratio of E/NE were decreased in the brain stem, and this ratio was increased in the heart. In hydralazine-treated rats, the catecholamine levels were unchanged in the brain stem and heart. The turnover rate of NE was significantly reduced in the brain stem and heart of MK-421-treated rats, whereas, after hydralazine, the turnover rate in the heart was increased (decreasing the half-life of NE by about 50%), indicating increased sympathetic activity. Thus, elimination of angiotensin II (AII) by CEI is associated with decreased sympathetic activity in both the brain stem and heart, whereas an equipotent antihypertensive action by smooth muscle relaxation leads to stimulation of both the renin-angiotensin and the sympathetic systems. These differences are more readily apparent by measurement of catecholamine turnover rates in tissues than of catecholamine levels, and they may account for the different hemodynamic effects of the two agents, even though both drugs act through arteriolar dilation.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6327520     DOI: 10.1161/01.hyp.6.2_pt_2.i1

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  7 in total

Review 1.  Angiotensin converting enzyme inhibitors and moderate hypertension.

Authors:  D McAreavey; J I Robertson
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

2.  Enalapril versus combined enalapril and nadolol treatment: effects on blood pressure, heart rate, humoral variables, and plasma potassium at rest and during exercise in hypertensive patients.

Authors:  P A Sullivan; B Daly; R O'Connor
Journal:  Cardiovasc Drugs Ther       Date:  1992-06       Impact factor: 3.727

3.  Enalapril reduces the catecholamine response to exercise in patients with heart failure.

Authors:  B P McGrath; L F Arnolda
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 4.  Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  P A Todd; R C Heel
Journal:  Drugs       Date:  1986-03       Impact factor: 9.546

5.  Effects of riboflavin analogues and diuretics on the spontaneously hypertensive rat heart.

Authors:  M Bhaskar; D Trachewsky; R D Stith; Y S Reddy
Journal:  Basic Res Cardiol       Date:  1990 Sep-Oct       Impact factor: 17.165

Review 6.  The renin-angiotensin system in the control of systemic arterial pressure.

Authors:  A B Ribeiro; O Kohlmann; M A Saragoça; O Marson; O L Ramos
Journal:  Drugs       Date:  1985       Impact factor: 9.546

7.  Effects of the converting enzyme inhibitor trandolapril on short-term variability of blood pressure in essential hypertension.

Authors:  C Dutrey-Dupagne; A Girard; A Ulmann; J L Elghozi
Journal:  Clin Auton Res       Date:  1991-12       Impact factor: 4.435

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.